Krka d d : Unaudited consolidated financial statements of the Krka Group and the Krka company for 2023

2023 Unaudited Consolidated

Financial Statements of the Krka Group and

Unaudited Financial Statements of

Krka, d. d., Novo mesto

with Relevant Notes

Novo mesto, March 2024

2023 Unaudited Consolidated Financial Statements of the Krka Group and Unaudited Financial Statements of Krka, d. d., Novo mesto

CONTENTS
At a glance	3
Financial highlights	4
Performance analysis	5
Sales	8
Research and development	10
Investments	12
Employees	13
Investor and share information	13
Sustainable operations	13
Subsequent events	14
Unaudited consolidated statement of financial position of the Krka Group	15
Unaudited consolidated income statement of the Krka Group	16
Unaudited consolidated statement of other comprehensive income of the Krka Group	16
Unaudited consolidated statement of changes in equity of the Krka Group	17
Unaudited consolidated statement of cash flows of the Krka Group	19
Unaudited statement of financial position of Krka, d. d. , Novo mesto	20
Unaudited income statement of Krka, d. d., Novo mesto	21
Unaudited statement of other comprehensive income of Krka, d. d., Novo mesto	21
Unaudited statement of changes in equity of Krka, d. d., Novo mesto	22
Unaudited statement of cash flows of Krka, d. d., Novo mesto	24

2

2023 Unaudited Consolidated Financial Statements of the Krka Group and Unaudited Financial Statements of Krka, d. d., Novo mesto

Based on the provisions of the Ljubljana Stock Exchange Rules and Article 17 of Regulation (EU) No 596/2014,

Krka, d. d., Novo mesto hereby presents

2023 UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS OF THE KRKA

GROUP AND UNAUDITED FINANCIAL STATEMENTS OF KRKA, D. D.,

NOVO MESTO WITH RELEVANT NOTES

The 2023 unaudited consolidated financial statements of the Krka Group and unaudited financial statements of Krka, d. d., Novo mesto with comparative data for 2022 have been prepared in accordance with the International Financial Reporting Standards (IFRS). The 2022 comparative statements have been audited.

Krka, d. d., Novo mesto has no authorised capital and has made no conditional share capital increase.

At a glance

Krka, d. d., Novo mesto (hereinafter the Company, Krka, or the controlling company) is the controlling company of the Krka Group, which comprised the following subsidiaries as at 31 December 2023:

	Ownership share
	of the controlling company
	31 Dec 2023 (%)
TERME KRKA, d. o. o., Novo mesto	100
KRKA-FARMA d.o.o., Zagreb, Croatia	100
KRKA ROMANIA S.R.L., Bucharest, Romania	100
KRKA-FARMA DOO BEOGRAD, Belgrade, Serbia	100
KRKA-FARMA DOOEL Skopje, Skopje, North Macedonia	100
KRKA Bulgaria EOOD, Sofia, Bulgaria	100
KRKA HELLAS E.P.E., Athens, Greece	100
KRKA FARMA d.o.o., Sarajevo, Sarajevo, Bosnia and Herzegovina	100
KRKA-RUS LLC, Istra, Russian Federation	100
KRKA FARMA LLC, Istra, Russian Federation	100
KRKA UKRAINE LLC, Kiev, Ukraine	100
LLC 'KRKA Kazakhstan', Almaty, Kazakhstan	100
KRKA - POLSKA Sp. z o.o., Warsaw, Poland	100
KRKA ČR, s. r. o., Prague, Czechia	100
KRKA Magyarország Kft., Budapest, Hungary	100
KRKA Slovensko, s.r.o., Bratislava, Slovakia	100
UAB KRKA Lietuva, Vilnius, Lithuania	100
SIA KRKA Latvija, Riga, Latvia	100
TAD Pharma GmbH, Cuxhaven, Germany	100
Krka Sverige AB, Stockholm, Sweden	100
KRKA Pharma GmbH, Wien, Vienna, Austria	100
KRKA Farmacêutica, Unipessoal Lda., Estoril, Portugal	100
KRKA FARMACÉUTICA, S.L., Madrid, Spain	100
KRKA Farmaceutici Milano S.r.l., Milan, Italy	100
KRKA France Eurl, Paris, France	100
KRKA PHARMA DUBLIN LIMITED, Dublin, Ireland	100
KRKA Belgium, SA, Brussels, Belgium	100
KRKA Finland Oy, Espoo, Finland	100
KRKA UK LTD, London, United Kingdom	100
123 Acurae Pharma GmbH, Cuxhaven, Germany	100
KRKA Netherlands B.V., Breskens, Netherlands	100
Ningbo Krka Menovo Pharmaceutical Company Limited, Ningbo, China	60
KRKA USA LLC, Wilmington, United States of America	100
KRKA GCC L.L.C., Dubai, United Arab Emirates	100

As at 31 December 2023, the subsidiary Terme Krka, d. o. o. held a 100-percent interest in Golf Grad Otočec, d. o. o., Slovenia, while the subsidiary KRKA France Eurl held a 100-percent interest in HCS bvba in Belgium. The Chinese company Ningbo Menovo Pharmaceutical Co. Ltd. owns 40% of Ningbo Krka Menovo Pharmaceutical Co. Ltd.

3

2023 Unaudited Consolidated Financial Statements of the Krka Group and Unaudited Financial Statements of Krka, d. d., Novo mesto

Financial highlights

			Krka Group			Company
	€ thousand		2023	2022		Index	2023	2022		Index
Revenue		1,806,391	1,717,453		105	1,674,572	1,553,514	108
- Of that revenue from contracts with		1,798,969	1,708,542		105	1,449,739	1,356,075	107
	customers (products and services)
Gross profit		1,026,709	974,393		105	888,427	890,182		100
Earnings before interest, tax, depreciation		504,215	488,895		103	402,547	440,086		91
and amortisation (EBITDA)
Operating profit (EBIT)1		399,621	381,211		105	322,308	357,870		90
Profit before tax (EBT)		367,126	433,073		85	329,049	412,258		80
Net profit		313,732	363,662		86	294,481	348,215		85
Effective tax rate		14.5%	16.0%			10.5%	15.5%
R&D expenses		178,582	162,580		110	173,783	158,292		110
Investments		131,932	105,974		124	111,751	79,540		140

	31 Dec 2023	31 Dec 2022		Index	31 Dec 2023	31 Dec 2022	Index
Non-current assets	1,059,267	1,125,025	94	1,076,235	1,123,594	96
Current assets	1,705,024	1,562,475	109	1,537,636	1,392,950	110
- Inventories	604,621	553,332	109	513,892	492,978	104
- Trade receivables	509,070	402,730	126	463,126	357,889	129
- Cash and cash equivalents	174,011	518,934	34	140,993	470,297	30
Equity	2,181,766	2,138,509	102	2,133,258	2,060,792	104
Non-current liabilities	149,218	132,130	113	118,930	102,333	116
Current liabilities	433,307	416,861	104	361,683	353,419	102
- Trade payables	153,762	140,837	109	175,847	194,143	91
RATIOS		2023		2022		2023		2022
Gross profit margin	56.8%		56.7%	53.1%		57.3%
EBITDA margin	27.9%		28.5%	24.0%		28.3%
EBIT margin	22.1%		22.2%	19.2%		23.0%
EBT margin	20.3%		25.2%	19.6%		26.5%
Net profit margin (ROS)	17.4%		21.2%	17.6%		22.4%
Return on equity (ROE)2	14.5%		17.9%	14.0%		17.7%
Return on assets (ROA)3	11.5%		13.9%	11.5%		14.1%
Liabilities/Equity	0.267		0.257	0.225		0.221
R&D expenses/Revenue		9.9%		9.5%	10.4%		10.2%
NUMBER OF EMPLOYEES		2023		2022		2023		2022
Year-end	11,780		11,598	6,509		6,320
Average	11,667		11,569	6,411		6,254
KRKA GROUP SHARE INFORMATION				2023		2022		Index
Total number of shares issued				32,793,448	32,793,448		100
Earnings per share (EPS) in €4				10.14	11.69		87
Gross dividend per share in €				6.60		5.63		117
Closing price at the end of the year in €5				110.00	92.00		120
Price/Earnings ratio (P/E)				10.85		7.87		138
Book value in €6				66.53	65.21		102
Price/Book value (P/B)				1.65		1.41		117
Market capitalisation in € thousand (31 Dec)			3,607,279	3,016,997		120

1. The difference between operating income and expenses
2. Net profit/Average shareholders' equity in the year
3. Net profit/Average total asset balance in the year
4. Net profit for the year attributable to majority equity holders of the Krka Group/Average number of shares issued in the year, excluding treasury shares
5. Share price on the Ljubljana Stock Exchange
6. Equity as at 31 Dec/Total number of shares issued

4

2023 Unaudited Consolidated Financial Statements of the Krka Group and Unaudited Financial Statements of Krka, d. d., Novo mesto

Krka Group performance analysis

Operating income

Sales
	2000					1,806	20
	1800				1,717	18
			1,566
	1600	1,493	1,535		17.5	16
			16.6
	1400		15.5	15.9		14
	14.4			solid forms
million	1200					12
1000						10
€	800						8	Billion
600						6
	400						4
	200						2
	0						0
		2019	2020	2021	2022	2023
			Revenue		Sales volume

In 2023, the Krka Group generated revenue of €1,806.4 million, an €88.9 million or 5% increase on 2022, of which revenue from contracts with customers on sales of products and services reached €1,799.0 million and revenue from contracts with customers on sales of materials and other sales revenue constituted the difference. Over the past five years, average annual sales grew by 4.2% in volume and 6.3% in value.

Operating expenses

The Krka Group posted operating expenses totalling €1,412.9 million, up €67.5 million or 5% on 2022.

Krka Group operating expenses comprised: cost of goods sold totalling €779.7 million; selling and distribution expenses totalling €347.9 million; R&D expenses totalling €178.6 million; and general and administrative expenses totalling €106.8 million. Operating expenses accounted for 78% of revenue and, over the past five years, ranged between 75% in 2020 and 83% in 2019.

Cost of goods sold, up 5% on 2022, represented the largest item in the Krka Group operating expense structure. They accounted for 43.2% of total revenue in 2023 and 43.3% in 2022. Selling and distribution expenses remained at the 2022 level and accounted for 19.3% of total revenue, down 1.0 percentage point on 2022. R&D expenses constituted 9.9% of total revenue (up 0.4 percentage points on 2022) and increased by 10%. General and administrative expenses amounted to 5.9% of total revenue, up 18%, while their proportion in revenue increased by 0.6 percentage points.

Financial income and expenses

The Krka Group operates in diverse international environments and is exposed to foreign exchange risks in certain sales and purchase markets.

The cumulative amount of net foreign exchange differences and net income from currency risk hedging of the Krka Group generated a total loss of €38.8 million in 2023. Of that, net foreign exchange losses, arising primarily from the depreciation of the Russian rouble, totalled €38.3 million; derivatives income totalled €4.3 million; and derivatives expenses totalled €4.8 million. Interest income totalled €11.2 million and dividend income €0.8 million. Financial expenses consisted of interest expense of €0.5 million and other financial expenses of €12.5 million.

5

2023 Unaudited Consolidated Financial Statements of the Krka Group and Unaudited Financial Statements of Krka, d. d., Novo mesto

The Krka Group recorded net financial loss of €32.5 million in 2023. In 2022, the Krka Group generated net financial gain of €51.9 million.

Operating results

EBITDA, EBIT, and net profit

€ million

550

500

450

400

350

300

250

200

150

100

50

0

		502		489	504
			464
385		391		381	400
			355		364
	274	289	308		314
	244

2019	2020	2021	2022	2023
		EBITDA		EBIT			Net profit

The Krka Group recorded EBIT totalling €399.6 million, up €18.4 million or 5% on 2022. The Krka Group posted EBITDA totalling €504.2 million, up €15.3 million or 3%. Over the past five years, annual EBIT growth averaged 11.4% and annual EBITDA growth averaged 8.0%.

In 2023, profit before tax of the Krka Group decreased by €65.9 million or 15% to €367.1 million. Its effective tax rate was 14.5%. The Krka Group recorded net profit totalling €313.7 million, down €49.9 million or 14% on 2022. Profit before tax and net profit decreased year on year primarily owing to the depreciation of the rouble against the euro in 2023 and strong rouble appreciation in the year before. Over the past five years, average annual net profit growth was 12.5%.

Assets

		Share		Share
€ thousand	31 Dec 2023	(%)	31 Dec 2022	(%)	Index
Non-current assets	1,059,267	38.3	1,125,025	41.9	94
Property, plant and equipment	790,345	28.6	779,336	29.0	101
Intangible assets	102,348	3.7	102,550	3.8	100
Investments and loans	117,772	4.2	188,309	7.0	63
Other	48,802	1.8	54,830	2.1	89
Current assets	1,705,024	61.7	1,562,475	58.1	109
Inventories	604,621	21.9	553,332	20.6	109
Trade receivables	509,070	18.4	402,730	15.0	126
Other	591,333	21.4	606,413	22.5	98
Total assets	2,764,291	100.0	2,687,500	100.0	103

At the end of 2023, Krka Group assets were valued at €2,764.3 million, a €76.8 million or 3% increase on year- end 2022. The ratio of non-current to current assets in the overall asset structure differed from that recorded at year-end 2022, as non-current assets decreased by 3.6 percentage points and totalled 38.3%.

Krka Group non-current assets were valued at €1,059.3 million, a €65.8 million or 6% decrease on year-end 2022. The most important item in the Krka Group asset structure was property, plant and equipment (PP&E). It was valued at €790.3 million and accounted for 28.6% of total Krka Group assets. Intangible assets amounted to €102.3 million and accounted for 3.7% of total assets.

6

2023 Unaudited Consolidated Financial Statements of the Krka Group and Unaudited Financial Statements of Krka, d. d., Novo mesto

Krka Group current assets were valued at €1,705.0 million and increased by €142.5 million or 9% on year- end 2022. Inventories amounted to €604.6 million or 21.9% of total Krka Group assets. Trade receivables due from customers outside the Krka Group totalled €509.1 million, accounting for 18.4% of total Krka Group assets. Inventories increased by €51.3 million or 9% and trade receivables increased by €106.3 million or 26%. Krka Group current loans totalled €58.7 million or 2.1% of its total assets and included a €50.0 million deposit with maturity of more than 90 days and less than one year with at a foreign bank with a high credit rating. Investments at fair value through profit or loss totalled €236.8 million and represented investments into treasury bills of western European EU countries with a high credit rating. Cash and cash equivalents were valued at €174.0 million, down €344.9 million on year-end 2022, accounting for 6.3% of Krka Group total assets. From the beginning until the end of 2023, cash and cash equivalents decreased primarily on the back of reallocation of surplus cash investments. We transferred a portion of cash and cash equivalents to current loans, while the majority was transferred to investments at fair value through profit or loss. We reallocated investments to disperse credit risk and maturity of individual investments.

Equity and liabilities

		Share		Share
€ thousand	31 Dec 2023	(%)	31 Dec 2022	(%)	Index
Equity	2,181,766	78.9	2,138,509	79.6	102
Non-current liabilities	149,218	5.4	132,130	4.9	113
Current liabilities	433,307	15.7	416,861	15.5	104
Total equity and liabilities	2,764,291	100.0	2,687,500	100.0	103

As at 31 December 2023, the Krka Group posted €43.3 million or 2% higher equity than at year-end 2022. The rise was attributable to Krka Group net profit totalling €313.7 million and acquisition of non-controlling interests totalling €1.3 million. Equity declined due to other comprehensive income net of tax totalling €53.5 million, dividends paid totalling €204.4 million, and repurchase of treasury shares totalling €13.9 million.

The Krka Group recorded provisions of €124.4 million, up €17.2 million on year-end 2022 due to higher post- employment and other non-current employee benefits, which increased by €17.3 million to €113.3 million. Provisions for lawsuits amounted to €10.6 million and remained unchanged. Other provisions amounted to €0.5 million, down €0.1 million.

Of Krka Group current liability items, trade payables increased by €12.9 million (of which payables to domestic suppliers increased by €1.7 million and payables to suppliers abroad by €11.3 million). Current liabilities from contracts with customers increased by €4.5 million (of which bonuses and volume rebates increased by €6.4 million and right of return by €0.8 million, while contract liabilities decreased by €2.7 million). Other current liabilities increased by €18.6 million, of which payables to employees increased by €19.0 million.

Cash flow statement

€ thousand	2023	2022
Net cash flow from operating activities	227,254	467,651
Net cash flow from investing activities	-343,235	76,414
Net cash flow from financing activities	-229,822	-187,022
Net change in cash and cash equivalents	-345,803	357,043

Net change in Krka Group cash and cash equivalents (exclusive of exchange rate fluctuations) yielded a decrease of €345.8 million in 2023, because the positive cash flow from operating activities was lower than the negative cash flow from investing and financing activities.

The Krka Group generated €446.5 million operating profit before changes in net current assets. Changes in current assets that had a positive impact on cash flow consisted of changes in trade payables, provisions, and other current liabilities, while changes in trade receivables, inventories, and deferred revenue had a negative impact. Income tax paid further decreased net cash flow from operating activities.

7

2023 Unaudited Consolidated Financial Statements of the Krka Group and Unaudited Financial Statements of Krka, d. d., Novo mesto

Negative cash flow from investing activities totalling €343.2 million were primarily generated from net payments for current investments totalling €209.5 million and acquisition of property, plant and equipment of €130.0 million. Negative cash flows from financing activities totalling €229.8 million primarily resulted from dividends paid and other profit shares of €204.4 million and repurchased treasury shares of €13.9 million.

Performance ratios

35

30

25

20

%

15

10

5

0

32.7
29.628.527.9
25.8	25.5
28.9	22.722.2 22.1
	18.819.721.2
18.4		17.9
22.2		17.4
	16.4	18.7	15.216.916.8	14.5	13.9
				16.3		11.713.112.9	11.5
						12.6

EBITDA margin		EBIT margin			Profit margin	ROE	ROA
		2019		2020		2021			2022			2023	average

Performance ratios are in line with the Krka Group's key strategic objectives.

Sales

Krka Group product and service sales by region

		Share		Share
€ thousand	2023	(%)	2022	(%)	Index
Region Slovenia	113,777	6.3	103,047	6.0	110
Region South-East Europe	249,330	13.9	224,523	13.1	111
Region East Europe	593,951	33.0	623,377	36.5	95
Region Central Europe	397,079	22.1	364,154	21.3	109
Region West Europe	369,624	20.5	327,343	19.2	113
Region Overseas Markets	75,208	4.2	66,098	3.9	114
Total	1,798,969	100.0	1,708,542	100.0	105

In 2023, the Krka Group generated €1,799.0 million revenue from contracts with customers on sales of products and services, an increase of €90.4 million or 5% on the 2022 results. We recorded sales growth in most sales markets.

Region East Europe recorded the highest sales, €594.0 million or 33.0% of total Krka Group sales, down 5% year on year. In the Russian Federation, we made €346.8 million in product sales, a 10% drop on 2022. Sales growth denominated in Russian roubles reached 15% compared to 2022, while sales volume climbed by 7%. The difference between the euro and the rouble sales indices resulted from the considerable depreciation of the rouble. We pay special attention to Russian rouble risk management. The reduced availability of financial instruments saw us focus on natural risk mitigation methods of currency exposure in 2023. Last year, we manufactured more than 77% of all Krka products on demand in the Russian Federation in our subsidiary Krka- Rus. We recorded growth in all other regional markets, except Ukraine and Turkmenistan. In Ukraine, product sales added up to €83.4 million, resulting in 12% drop on 2022.

8

2023 Unaudited Consolidated Financial Statements of the Krka Group and Unaudited Financial Statements of Krka, d. d., Novo mesto

Region Central Europe, comprising the Visegrad Group and the Baltic states, followed with sales of €397.1 million or 22.1% of total Krka Group sales. We reached 9% year-on-year growth. Poland, the leading market in the region, generated product sales of €180.8 million and recorded 8% growth. In Czechia, product sales increased by 9% to €60.9 million and in Hungary by 11% to €52.3 million. We increased sales also in all other countries in the region.

Region West Europe ranked third in terms of sales with €369.6 million or 20.5% of total Krka Group sales. Year on year, sales were up 13%. The region's largest market was Germany, where product sales totalled €105.9 million and reached 20% growth. It was followed by the Scandinavian countries, Portugal, and Italy. Germany, the Scandinavian countries, Portugal, and the United Kingdom recorded strongest absolute growth in sales.

Product sales in Region South-East Europe amounted to €249.3 million, up 11% on 2022, accounting for 13.9% of total Krka Group sales. Romania and Croatia remained our two leading markets in the region. We recorded the highest absolute sales growth in Romania, Serbia, and Croatia. We generated product sales of €72.4 million in Romania, reaching 15% growth, and €46.0 million in sales in Croatia, recording 12% growth. Sales increased in all markets in the region.

In Region Slovenia, sales of products and services totalled €113.8 million, accounting for 6.3% of total Krka Group sales. Sales grew by 10%. Product sales of €66.1 million constituted the bulk of sales total, recording 9% growth. Health resort and tourist services yielded €47.7 million, a 12% rise on 2022.

Region Overseas Markets accounted for a 4.2% share in total Krka Group sales and yielded €75.2 million in product sales, a 14% year-on-year climb.

Krka Group sales by product and service group

		Share		Share
€ thousand	2023	(%)	2022	(%)	Index
Human health products	1,646,633	91.6	1,572,949	92.1	105
- Prescription pharmaceuticals	1,469,381	81.7	1,390,972	81.4	106
- Non-prescription products	177,252	9.9	181,977	10.7	97
Animal health products	104,640	5.8	93,041	5.4	112
Health resort and tourist services	47,696	2.6	42,552	2.5	112
Total	1,798,969	100.0	1,708,542	100.0	105

Sales of prescription pharmaceuticals totalled €1,469.4 million, up 6% on 2022, accounting for 81.7% of total Krka Group product and service sales. We increased sales in all regions, except Region East Europe, ranging as follows: 14% Region Overseas Markets;

14% Region West Europe;

13% Region South-East Europe;

8% Region Slovenia; and

8% Region Central Europe.

Among our ten largest individual markets, sales growth of prescription pharmaceuticals was the highest in Germany, Poland, Romania, and the Scandinavian countries, and among our other markets in the United Kingdom. Top-ranking therapeutic classes of prescription pharmaceuticals included cardiovascular agents, central nervous system agents, gastrointestinal tract medicines, and pain relievers.

The ten leading prescription pharmaceuticals in terms of sales were product groups containing:

• perindopril (Prenessa*, Co-Prenessa*, Amlessa*, Co-Amlessa*, Roxiper*, Roxampex*);
• valsartan (Valsacor*, Valsacombi*, Vamloset*, Co-Vamloset*, Valarox*);
• rosuvastatin (Roswera*, Co-Roswera*);
• losartan (Lorista*, Lorista H*, Lorista HD*, Tenloris*);
• pantoprazole (Nolpaza*);
• atorvastatin (Atoris*);
• esomeprazole (Emanera*);

9

2023 Unaudited Consolidated Financial Statements of the Krka Group and Unaudited Financial Statements of Krka, d. d., Novo mesto

• tramadol (Doreta*, Tadol*);
• candesartan (Karbis*, Karbicombi*, Kandoset*); and
• naproxen (Nalgesin*).

Sales of non-prescription products totalled €177.3 million, down 3% on 2022, accounting for 9.9% of total Krka Group sales. Changing rates of the Russian rouble caused the drop in sales value. Sales volume of non-prescription products in the Russian Federation, however, saw a 5% increase. In 2023, we recorded the highest sales increases in Uzbekistan, Slovenia, and Czechia. Septolete*, Nalgesin*, Herbion*, and Septanazal* were our most important non-prescription product brands in terms of sales.

Sales of animal health products grew by 12% and amounted to €104.6 million (5.8% of total sales). Sales generated in the Russian Federation, Poland, and Germany contributed most to the growth. The combination of milbemycin and praziquantel (Milprazon*) was our best-selling animal health product. It was followed by products containing fipronil (Fypryst*, Fypryst* Combo), selamectin (Selehold*), enrofloxacin (Enroxil*), and products combining pyrantel and praziquantel (Dehinel*, Dehinel* Plus).

Health resort and tourist services yielded €47.7 million, up 12% on 2022 (2.6% of total sales). We recorded 336,174 overnight stays, a 4% year-on-year increase.

2023 sales of leading products in terms of value

perindopril ± indapamide ± amlodipine ± rosuvastatin (PRENESSA*) valsartan ± hydrochlorothiazide ± amlodipine ± rosuvastatin (VALSACOR) rosuvastatin ± ezetimib (ROSWERA*) losartan ± hydrochlorothiazide ± amlodipine (LORISTA*) pantoprazole (NOLPAZA*) atorvastatin ± amlodipine (ATORIS) esomeprazole (EMANERA*)

SEPTOLETE tramadol ± paracetamol (DORETA*) candesartan ± hydrochlorothiazide ± amlodipine (KARBIS*) naproxen (NALGESIN*)

telmisartan ± hydrochlorothiazide ± amlodipine (TOLURA*) milbemycin ± praziquantel (MILPRAZON)

enalapril ± hydrochlorothiazide ± lercanidipine (ENAP)

sitagliptin ± metmorfin (MAYSIGLU*)

182

158

94

87

86

76

57

47

35

35

33

30

27

26

25

0	20	40	60	80	100	120	140	160	180	200
					€ million

*Sales of leading products are presented by leading active ingredient. Combination medicines that incorporate this active ingredient are also included. Products marketed under different product brand names or the Krka trademark in individual markets are marked with an asterisk.

Research and development

In 2023, we expanded our product range with fourteen new products, including ten new prescription pharmaceuticals, two additions to our portfolio of consumer health products and food supplements, and two veterinary medicines.

10